Loading
companiesCompany
Philogen S.p.A.
Philogen S.p.A. is a Italy-based biotechnology company running 8 late-stage cancer trials of Onfekafusp alfa and onfekafusp alfa in melanoma, glioma & glioblastoma and basal cell carcinoma.
Overview
Philogen S.p.A., based in Siena, Italy, is a biotechnology company listed as BIT:PHIL. Philogen is a biotechnology company developing targeted cancer therapeutics based on antibodies and small molecules directed at the tumour microenvironment. On ClinicalTrials.gov it is the lead sponsor of 8 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing Onfekafusp alfa and onfekafusp alfa in melanoma, glioma & glioblastoma, basal cell carcinoma and sarcomas. The largest, NCT04443010 (Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma), plans to enrol 226 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Siena, IT
Scorecard
All companies#353of 1244 companies, score 11
- phase 3 +3
- modalities +2
- registry trials +6
0 approved, 1 in phase 3, 0 earlier, 0 targets, 9 registry studies. Formula on the scorecards page.
Type
Biotech · BIT:PHIL
Stage
Public
Website
Founded
1996
Phase 3Intralesional immunocytokine combination
Daromun is a pair of antibody-linked immune messengers injected straight into melanoma deposits before surgery. In a phase 3 trial it lowered the chance of the melanoma coming back after the operation compared with surgery alone.
Similar pages
- TechnologyImmunocytokines (antibody-cytokine fusions)
Shares Daromun, Sarcomas (soft tissue, bone, GIST), Melanoma.
- TargetKNL1
Shares Basal cell carcinoma, Glioma & glioblastoma, Melanoma.
- CancerLocally advanced and metastatic basal cell carcinoma
Shares L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC), L19IL2/TNF in Patients With Basal Cell Carcinoma, Basal cell carcinoma.
- CancerStage III melanoma (after surgery)
Shares Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients, Neoadjuvant L19IL2/L19TNF- Pivotal Study, Daromun, Melanoma.
- TargetNACA
Shares Basal cell carcinoma, Melanoma.
- TargetOCA2
Shares Basal cell carcinoma, Melanoma.
- InstitutionSkcin (the Karen Clifford Skin Cancer Charity)
Shares Basal cell carcinoma, Melanoma.
- TargetSLC45A2
Shares Basal cell carcinoma, Melanoma.
cancers
drugs
Phase 3Intralesional immunocytokine combination
trials
A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or RecurrenceEfficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue SarcomaEfficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma PatientsL19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)L19IL2/TNF in Patients With Basal Cell CarcinomaNeoadjuvant L19IL2/L19TNF- Pivotal StudySafety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed GlioblastomaStudy of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients